-
Autor
Anker, Stefan D 1 Bocchi, Edimar 1 Brueckmann, Martina 1 Butler, Javed 1 Böhm, Michael 1 Choi, Dong-Ju 1 Chopra, Vijay 1 Chuquiure, Eduardo 1 Ferreira, João Pedro 1 Filippatos, Gerasimos 1 Giannetti, Nadia 1 Gomez-Mesa, Juan Esteban 1 González-Juanatey, José R 1 Iwata, Tomoko 1 Janssens, Stefan 1 Januzzi, James L 1 Merkely, Bela 1 Nicholls, Stephen J 1 Perrone, Sergio V 1 Piña, Ileana L 1
-
Pracoviště
1st Department of Medicine Faculty of... 1 Argentine Catholic University Buenos ... 1 Baylor Scott and White Research Insti... 1 Boehringer Ingelheim International In... 1 Boehringer Ingelheim Pharma GmbH and ... 1 Boehringer Ingelheim Pharmaceuticals ... 1 Cardiology Department University Hosp... 1 Cardiology Service Fundación Valle de... 1 Cardiovascular Department Cardiology ... 1 Cardiovascular Research and Developme... 1 Central Michigan University Mount Ple... 1 Department of Cardiology partner site... 1 Department of Cardiovascular Diseases... 1 Department of Cardiovascular Medicine... 1 Department of Medicine Seoul National... 1 FLENI and IADT Institute Buenos Aires... 1 Heart Failure Center Fuwai Hospital C... 1 Heart Failure Clinics Instituto do Co... 1 Heart and Vascular Center Semmelweis ... 1 Institute of Heart Diseases Wrocław M... 1
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Nejvíce citované
-
Autor
Anker, Stefan D 1 Bocchi, Edimar 1 Brueckmann, Martina 1 Butler, Javed 1 Böhm, Michael 1 Choi, Dong-Ju 1 Chopra, Vijay 1 Chuquiure, Eduardo 1 Ferreira, João Pedro 1 Filippatos, Gerasimos 1 Giannetti, Nadia 1 Gomez-Mesa, Juan Esteban 1 González-Juanatey, José R 1 Iwata, Tomoko 1 Janssens, Stefan 1 Januzzi, James L 1 Merkely, Bela 1 Nicholls, Stephen J 1 Perrone, Sergio V 1 Piña, Ileana L 1
-
Pracoviště
1st Department of Medicine Faculty of... 1 Argentine Catholic University Buenos ... 1 Baylor Scott and White Research Insti... 1 Boehringer Ingelheim International In... 1 Boehringer Ingelheim Pharma GmbH and ... 1 Boehringer Ingelheim Pharmaceuticals ... 1 Cardiology Department University Hosp... 1 Cardiology Service Fundación Valle de... 1 Cardiovascular Department Cardiology ... 1 Cardiovascular Research and Developme... 1 Central Michigan University Mount Ple... 1 Department of Cardiology partner site... 1 Department of Cardiovascular Diseases... 1 Department of Cardiovascular Medicine... 1 Department of Medicine Seoul National... 1 FLENI and IADT Institute Buenos Aires... 1 Heart Failure Center Fuwai Hospital C... 1 Heart Failure Clinics Instituto do Co... 1 Heart and Vascular Center Semmelweis ... 1 Institute of Heart Diseases Wrocław M... 1
- Publikační typ
- Check Tag
- Kategorie
- Jazyk
- Země
- Časopis/zdroj
- Nejvíce citované
-
Anker, Stefan D
Autor Anker, Stefan D ORCID Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany. s.anker@cachexia.de Institute of Heart Diseases, Wrocław Medical University, Wrocław, Poland. s.anker@cachexia.de
- Butler, Javed
- Usman, Muhammad Shariq
- Filippatos, Gerasimos
-
Ferreira, João Pedro
Autor Ferreira, João Pedro Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, and INSERM U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal
- Bocchi, Edimar
- Böhm, Michael
- Rocca, Hans Pieter Brunner-La
- Choi, Dong-Ju
- Chopra, Vijay
PubMed
36471037
PubMed Central
PMC9800272
DOI
10.1038/s41591-022-02041-5
PII: 10.1038/s41591-022-02041-5
Knihovny.cz E-zdroje
The EMPEROR-Preserved trial showed that the sodium-glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients with left ventricular ejection fraction (LVEF) > 40%. Here, we report the results of a pre-specified analysis that separately evaluates these patients stratified by LVEF: preserved (≥ 50%) (n = 4,005; 66.9%) or mid-range (41-49%). In patients with LVEF ≥ 50%, empagliflozin reduced the risk of cardiovascular death or HHF (the primary endpoint) by 17% versus placebo (hazard ratio (HR) 0.83; 95% confidence interval (CI): 0.71-0.98, P = 0.024). For the key secondary endpoint, the HR for total HHF was 0.83 (95%CI: 0.66-1.04, P = 0.11). For patients with an LVEF of 41-49%, the HR for empagliflozin versus placebo was 0.71 (95%CI: 0.57-0.88, P = 0.002) for the primary outcome (Pinteraction = 0.27), and 0.57 (95%CI: 0.42-0.79, P < 0.001) for total HHF (Pinteraction = 0.06). These results, together with those from the EMPEROR-Reduced trial in patients with LVEF < 40%, support the use of empagliflozin across the full spectrum of LVEF in heart failure.
- MeSH
- benzhydrylové sloučeniny terapeutické užití škodlivé účinky MeSH
- funkce levé komory srdeční MeSH
- glifloziny * terapeutické užití MeSH
- glukosidy terapeutické užití škodlivé účinky MeSH
- lidé MeSH
- srdeční selhání * farmakoterapie MeSH
- tepový objem MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
- Názvy látek
- benzhydrylové sloučeniny MeSH
- empagliflozin MeSH Prohlížeč
- glifloziny * MeSH
- glukosidy MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.